Share
Share
The fibrotic liver disease that is associated with Biliary Atresia (BA) impacts the likelihood of survival with native liver. Our previously research demonstrated the potential for a certain profibrotic signaling pathway to be active in BA. Using a mouse model of BA and human liver gene expression data collected by ChiLDReN, we were able to confirm the likely activation of this pathway known as TWEAK/FN14 in association with liver fibrosis. We further showed that inhibition of this pathway pharmacologically was associated with near complete elimination of fibrosis in the mouse model of BA. These observations suggest that focus on this signaling pathway warrants further study as we seek novel ways to care for infants with BA.
January 8, 2025 — Christopher Spera, President and CEO of Arbor Research Collaborative for Health, announced the election of Bryan K. Johnson, JD, MBA to the Arbor Research board of directors in 2025. Mr. Johnson was a co-founder of Insight Policy Research in 2001. His strategic development, operational management, and financial oversight led the start-up
December 5, 2024 — Arbor Research Collaborative for Health is proud to announce an innovative collaboration with the Nephrology Associates of Northern Illinois and Indiana (NANI), the largest private nephrology practice in the United States. This partnership marks a significant milestone in advancing chronic kidney disease (CKD) research and management by leveraging NANI’s extensive patient-level
Arbor Research Collaborative for Health is excited to announce a partnership with CSL Vifor to launch a multinational registry designed to capture real-world outcomes of difelikefalin (Kapruvia®), a newly-approved treatment for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis (HD) patients. Known as PARADIGM (PAn european Registry Addressing pruritus in DIalysis with a focus on Goal
The Health Resources and Services Administration (HRSA) has selected Arbor Research Collaborative for Health (Arbor Research) as one of 14 organizations who will lead the modernization of the Organ Procurement and Transplantation Network (OPTN). Arbor Research received one of the five initial efforts, focusing on improving patient safety and policy compliance systems and processes overseen